News
MD Anderson–led alliance seeks to advance leukemia drug development
The research collaboration will focus on novel therapies for AML, CML, ALL, myeloproliferative neoplasms, and myelofibrosis.
News
KTE-X19 induces durable CRs, MRD negativity in ALL
SAN DIEGO—An update of the ZUMA-3 trial showed that KTE-X19—an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy—can induce high...
News
Preliminary data suggest UCART19 is safe, effective
SAN DIEGO—Preliminary data on UCART19—the first off-the-shelf, anti-CD19, allogeneic chimeric antigen receptor (CAR) T-cell therapy—suggest it can...
News
Early switch to dasatinib offers clinical benefit to CML patients
SAN DIEGO—Early results of the DASCERN trial indicate that patients with chronic myeloid leukemia (CML) in chronic phase who have a suboptimal...
News
Dasatinib re-challenge feasible as 2nd attempt at TKI discontinuation
SAN DIEGO—Preliminary trial results suggest re-treatment with dasatinib is feasible and safe for a second attempt at tyrosine kinase inhibitor (...
News
P-BCMA-101 gains FDA regenerative medicine designation
The autologous CAR T-cell therapy being developed for multiple myeloma received regenerative medicine advanced therapy designation from the FDA....
News
Genomic abnormalities shed light on racial disparity in myeloma
The researchers relied on genetic ancestry, rather than self-reported race, to evaluate myeloma disparities.
News
Ground-breaking therapy comes with distinct challenges
NEW YORK—Two chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel (Yescarta ®) and tisagenlecleucel (Kymriah™)—are already...
News
Novel agents changing treatment algorithm in AML
NEW YORK—Recent drug approvals for acute myeloid leukemia (AML) have greatly expanded options for treating patients, according to a presentation...
News
Current management of AML patients
NEW YORK—A presentation at the NCCN 13th Annual Congress: Hematologic Malignancies outlined current practices for managing patients with acute...
News
Metabolic changes in T cells may limit CAR potential in kids
Researchers analyzed peripheral blood T cells from 157 pediatric cancer patients at diagnosis and after chemotherapy and found the potential to...
News
DLBCL survivors at greater risk of autoimmune, infectious diseases
ATLANTA—A population-based study indicates that, compared to other cancer survivors, patients who survive diffuse large B-cell lymphoma (DLBCL)...
News
Ixazomib/lenalidomide maintenance promising after ASCT in MM
ATLANTA—Adding ixazomib to lenalidomide as maintenance therapy for newly diagnosed multiple myeloma (MM) patients after upfront autologous stem...
News
Update reveals ongoing responses in ZUMA-1
ATLANTA—The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; KTE-C19) is showing consistent, ongoing responses...
News
Study highlights need for induction strategy in elderly, frail MM patients
ATLANTA—Initial results of the phase 2 HOVON-126 trial in newly diagnosed multiple myeloma (MM) patients have highlighted the need for an...